Plant-Made Nanobodies for Botulism Treatment
Plant-Made Nanobodies for Botulism Treatment
批准号:
8058704
负责人:
KEITH WYCOFF
金额:
$23.68万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-25 至 2013-06-30
关键词:
AffinityAmino Acid SequenceAntibodiesAntitoxinsBindingBiologicalBiological AssayBiotechnologyBontoxilysinBotulinum ToxinsBotulismCatalytic DomainCell membraneCellsCharacteristicsChimera organismCleaved cellCultured CellsCytosolDoseEndosomesEquus caballusEventExcisionGenesGoalsGrantHumanImmunoglobulin FragmentsImmunotherapyIn VitroInjectableLabelLaboratoriesLibrariesLightLlamaMechanical VentilatorsMetalloproteasesMonoclonal AntibodiesMotor NeuronsMusN-terminalNerveNeuronsParalysedPeptidesPhasePlanetsPlantsPoisoningProteinsRattusRecombinant ProteinsRecombinantsResearchResearch SupportS-nitro-N-acetylpenicillamineSerotypingSpinal CordSupportive careSymptomsSystemTechnologyTestingTherapeuticToxic effectToxicity TestsToxinWorkbasebotulism immune globulineffective therapyfluorophorein vivoneurotransmissionprotein aminoacid sequencepublic health prioritiesresearch studysuccessuptake
中文摘要
描述(申请人提供):本申请中描述的研究的最终目标是开发一种经济、安全和有效的治疗方法,可以逆转肉毒杆菌中毒的麻痹症状。如果成功实现这一目标,在发生肉毒杆菌毒素生物恐怖袭击的情况下,可以拯救无数人的生命。注射抗毒素抗体的目的是快速、彻底地将毒素从体内清除出去。目前可用的肉毒杆菌中毒免疫疗法(马抗毒素、人类肉毒杆菌免疫球蛋白、单抗)只能清除尚未到达运动神经元的毒素分子。一旦毒素的催化轻链到达运动神经元的胞浆,在那里它裂解参与神经传递的蛋白质,正常抗体就无法接触到它。这就是为什么肉毒杆菌神经毒素中毒的受害者可能需要在呼吸机上进行数周的支持性护理。我们建议使用一种新的单链可变片段-纳米体来对抗毒素轻链的催化部位,以及允许蛋白质穿透运动神经元胞浆的技术,以逆转毒素引起的瘫痪。我们将从我们的合作者James Marks博士(加州大学旧金山分校)的实验室的骆驼抗体库中分离出一个单域可变片段,它抑制毒素轻链切割其蛋白质底物的能力。我们将使用植物表达系统将该纳米体与各种细胞穿透肽的融合表达出来。然后,我们将测试这些纳米体融合进入原代大鼠神经元细胞并抑制毒素活性的能力。最后,我们将测试穿透细胞的纳米体在小鼠身上的毒性。
与公共卫生相关:肉毒杆菌毒素是已知的最致命的生物物质,恐怖分子很容易生产和使用它来造成大量伤亡。这使得制定有效和经济的对策来保护公众成为公共卫生的优先事项。这项由这笔赠款支持的研究将为利用植物生产高度保护、安全和经济的抗毒素疗法奠定基础。
英文摘要
DESCRIPTION (provided by applicant): The ultimate goal of the research described in this application is to develop an economical, safe and effective therapeutic that can reverse the paralytic symptoms of botulism. Success in achieving this goal could save countless lives in the event of a bioterrorist attack by botulinum toxin. The goal of administering an anti-toxin antibody is rapid and complete removal of the toxin from the body. Currently available immunotherapies for botulism (equine antitoxin, human botulism immune globulin, monoclonal antibodies) can remove only toxin molecules that have not yet reached motor neurons. Once the catalytic light chain of the toxin reaches the cytosol of motor neurons, where it cleaves proteins involved in neurotransmission, it is inaccessible to normal antibodies. This is why victims of botulinum neurotoxin poisoning may need supportive care on a respirator for many weeks. We propose using a new single-chain variable fragment, a nanobody, against the catalytic site of the toxin light chain, along with technology that allows proteins to penetrate into the cytosol of motor neurons, to reverse the paralysis caused by the toxin. We will start with a single-domain variable fragment, isolated from a llama antibody library in the laboratory of our collaborator, Dr James Marks (UCSF), that inhibits the ability of the toxin light chain to cleave it's protein substrate. We will express fusions of this nanobody to various cell-penetrating peptides, using a plant expression system. We will then test the ability of these nanobody fusions to enter primary rat neuron cells and inhibit toxin activity. Finally, we will test the toxicity of the cell-penetrating nanobody in mice.
PUBLIC HEALTH RELEVANCE: Botulinum toxin is the deadliest biological substance known, and would be easy for a terrorist to produce and use to cause large numbers of casualties. This makes developing an effective and economical countermeasure to protect the public a public health priority. The research supported by this grant will lay the groundwork for using plants to produce a highly protective, safe and economical antitoxin therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections
-
批准号:10766626
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2023
-
负责人:KEITH WYCOFF
-
依托单位:
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
-
批准号:10219129
-
项目类别:
-
资助金额:$18.17万
-
财政年份:2020
-
负责人:KEITH WYCOFF
-
依托单位:
Improving gene expression via Massively Parallel Synonymous Codon Variant Screening
-
批准号:9908223
-
项目类别:
-
资助金额:$29.86万
-
财政年份:2020
-
负责人:KEITH WYCOFF
-
依托单位:
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
-
批准号:10082224
-
项目类别:
-
资助金额:$26.29万
-
财政年份:2020
-
负责人:KEITH WYCOFF
-
依托单位:
A mucosally targeted MERS-CoV vaccine produced in plants
-
批准号:9141182
-
项目类别:
-
资助金额:$23.65万
-
财政年份:2017
-
负责人:KEITH WYCOFF
-
依托单位:
Exploiting Superinfection Exclusion To Express Polyclonal Antibodies In Plants
-
批准号:8781667
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:KEITH WYCOFF
-
依托单位:
A MERS-CoV Receptor Decoy
-
批准号:8780733
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:KEITH WYCOFF
-
依托单位:
A MERS-CoV Receptor Decoy
-
批准号:8981265
-
项目类别:
-
资助金额:$80.18万
-
财政年份:2014
-
负责人:KEITH WYCOFF
-
依托单位:
Targeted mutagenesis of plant genes by the CRISPR/Cas system
-
批准号:8713873
-
项目类别:
-
资助金额:$22.41万
-
财政年份:2014
-
负责人:KEITH WYCOFF
-
依托单位:
A MERS-CoV Receptor Decoy
-
批准号:9127085
-
项目类别:
-
资助金额:$77.34万
-
财政年份:2014
-
负责人:KEITH WYCOFF
-
依托单位:
Chimeric IgG/A Tumor Immunotherapy
-
批准号:8522804
-
项目类别:
-
资助金额:$27.68万
-
财政年份:2013
-
负责人:KEITH WYCOFF
-
依托单位:
Phase I clinical trial of an immunoadhesin antitoxin for anthrax
-
批准号:8469692
-
项目类别:
-
资助金额:$18.78万
-
财政年份:2013
-
负责人:KEITH WYCOFF
-
依托单位:
Final preclinical development of an immunoadhesin therapy for inhalation anthrax
-
批准号:8450067
-
项目类别:
-
资助金额:$71.51万
-
财政年份:2012
-
负责人:KEITH WYCOFF
-
依托单位:
Final preclinical development of an immunoadhesin therapy for inhalation anthrax
-
批准号:8268899
-
项目类别:
-
资助金额:$123.08万
-
财政年份:2012
-
负责人:KEITH WYCOFF
-
依托单位:
An immunoadhesin for treatment of hypercholesterolemia
-
批准号:8311591
-
项目类别:
-
资助金额:$28.26万
-
财政年份:2012
-
负责人:KEITH WYCOFF
-
依托单位:
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against
-
批准号:8076969
-
项目类别:
-
资助金额:$157.85万
-
财政年份:2011
-
负责人:KEITH WYCOFF
-
依托单位:
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against
-
批准号:8461222
-
项目类别:
-
资助金额:$114.51万
-
财政年份:2011
-
负责人:KEITH WYCOFF
-
依托单位:
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against
-
批准号:8262149
-
项目类别:
-
资助金额:$116.61万
-
财政年份:2011
-
负责人:KEITH WYCOFF
-
依托单位:
An Immunoadhesin Therapy for Inhalational Anthrax
-
批准号:7645285
-
项目类别:
-
资助金额:$134.54万
-
财政年份:2009
-
负责人:KEITH WYCOFF
-
依托单位:
An Immunoadhesin Therapy for Inhalational Anthrax
-
批准号:7807118
-
项目类别:
-
资助金额:$96.99万
-
财政年份:2009
-
负责人:KEITH WYCOFF
-
依托单位:
海外基金